Nuclea Biotechnologies Secures New Design Patent
PITTSFIELD — Nuclea Biotechnologies Inc. announced that it has secured a new U.S. design patent for the design of its beam-dump assembly, a mechanical component that will be utilized in multiple diagnostic applications.
The beam-dump assembly is used for the detection of low-abundance proteins within microfluidic-based environments. It identifies a change in biological samples by reading laser light. This detection instrument will be used for protein detection in Nuclea’s fatty-acid synthase (FAS), HER-2/neu, and CAIX diagnostic tests, with future potential use in additional diagnostic tests. The design patent is an important step for Nuclea as the company continues to expand its intellectual property surrounding its proprietary tests and methods.
“This is another milestone for Nuclea in developing new diagnostic-based technology as it relates to the analysis of fluids in a variety of diseases,” said Patrick Muraca, the company’s president and CEO.
Based in Pittsfield, Nuclea, with additional operations in Worcester and Cambridge, has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung, and prostate cancer, as well as for diabetes and other metabolic syndromes. Nuclea also performs research leading to novel molecular oncology companion diagnostics for the pharmaceutical and biotechnology industries.